Exclusive: Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in
Lonnie Moulder may have been in silent running mode in the 2 years since he closed the $5 billion sale of Tesaro to GlaxoSmithKline. But he hasn’t been idle.
Today during the China Healthcare Investment Conference in Shanghai, where Endpoints News is playing a co-sponsor role, Moulder’s taking the wraps off a biotech startup he’s put together that has assembled a pipeline with 7 drugs in it, a plan to add several more therapies and a quick vault into the clinic for a company with a small but fast-expanding team that is growing roots in China and the US — with Europe soon to be added to its global frame.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.